Mutational Load and T-Cell–Inflamed Microenvironment May Predict Response to Pembrolizumab

TOP - May 2017, Vol 10, No 2 - Immunotherapy
Chase Doyle

Orlando, FL—The advent of immunotherapy has led to durable clinical responses in a variety of malignancies, but identifying which patients will respond to treatment remains elusive. According to data presented at the 2017 Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium, predictive biomarkers may be close at hand.

Genetic analyses from 2 recent multicohort advanced solid tumor trials suggest that tumor mutational load and tumor T-cell inflammation, measured by gene-expression profiling, are independent determinants of response to anti–PD-1 therapy.

“Nonsynonymous mutational load and neoantigen load, as well as an 18-gene immune-related gene expression profile, were significantly associated with overall response to pembrolizumab across multiple indications. The predicted clinical utility of both mutational load and gene expression profile was similarly high in these cohorts, suggesting comparable individual diagnostic abilities,” said Tanguy Seiwert, MD, Assistant Professor of Medicine, University of Chicago, IL.

“Based on these data, mutational load and gene expression profiling may have utility in characterizing responses to anti–PD-1 and other cancer immunotherapies,” he added.

As Dr Seiwert reported, tumor mutational load has been shown to correlate with benefit from CTLA-4 and PD-1 immunotherapies in multiple tumor types, including melanoma, non–small-cell lung cancer, colorectal cancer, and urothelial cancer. At the same time, tumor T-cell inflammation, which correlates with T-cell infiltration, gamma interferon expression, and PD-L1 and PD-L2 expression, has been advanced as an alternative biomarker.

Using data from 2 multicenter, multicohort studies (KEYNOTE-012 and KEYNOTE-028), Dr Seiwert and colleagues examined the association between mutational load and progression-free survival in 153 patients with PD-L1–positive tumors—21 different tumor types—who had whole-exome sequencing available. Overall response was also evaluated in patients with whole-exome sequencing and measurable disease at baseline (n = 135). For tumor T-cell inflammation, expression values for 18 genes were used to determine whether the tumor was inflamed. Finally, the association between mutational load and gene-expression profiling was also explored in Moffitt and The Cancer Genome Atlas data sets.

According to Dr Seiwert, objective response to treatment was significantly associated with mutational load (P = .0001), neoepitope load (P = .0001), and gene-expression profile (P = .0004). More specifically, at a mutational load cutoff of 102, response rates exceeded 30% in patients with ≥102 mutations. For patients with tumors carrying <102 mutations, however, response rates dropped to 7%.

Gene-expression profiling was also significantly associated with overall survival (P = .0071). In addition, patients with more inflamed tumors had a response rate of 25%, compared with a response rate of only 2% for patients with noninflamed tumors.

Finally, in patients with high mutational load and tumor inflammation, response rates exceeded 38%. In patients with low mutational load and noninflamed tumors, however, response rates fell to 0%.

“Mutational load and tumor T-cell inflammation are common features of anti–PD-1 responsive tumors. Whether used separately or in combination, these markers appear to have a high positive and negative predictive value, and may have clinical utility,” Dr Seiwert concluded.

Related Items
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
TOP Web Exclusives published on September 11, 2018 in Immunotherapy
Immune Checkpoint Inhibitors: Test Your Knowledge Level
Eileen Koutnik-Fotopoulos
TOP Web Exclusives published on September 11, 2018 in Immunotherapy
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
JHOP Web Exclusives published on August 10, 2018 in Immunotherapy
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
JHOP Web Exclusives published on August 6, 2018 in Immunotherapy
Immunotherapy Plus Targeted Therapy Combination Active in Metastatic CRC
Charles Bankhead
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Immunotherapy
ASH Recaps “Phenomenal” Year for Acute Myeloid Leukemia Drug Approvals
Chase Doyle
TOP Web Exclusives published on April 9, 2018 in Leukemia
Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern
Chase Doyle
TOP Web Exclusives published on April 9, 2018 in Immunotherapy
Last modified: May 10, 2017